

Stanley Nattel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5060149/publications.pdf>

Version: 2024-02-01

657
papers

65,134
citations

553

130
h-index

1256

232
g-index

714
all docs

714
docs citations

714
times ranked

29974
citing authors

#	ARTICLE	IF	CITATIONS
1	Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance. <i>Cardiovascular Research</i> , 2023, 119, 614-630.	1.8	15
2	The effects of cardiac stretch on atrial fibroblasts: analysis of the evidence and potential role in atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 440-460.	1.8	18
3	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. <i>Cardiovascular Research</i> , 2022, 118, 2415-2427.	1.8	45
4	Rotors anchored by refractory islands drive torsades de pointes in an experimental model of electrical storm. <i>Heart Rhythm</i> , 2022, 19, 318-329.	0.3	6
5	The role of cellular senescence in cardiac disease: basic biology and clinical relevance. <i>Nature Reviews Cardiology</i> , 2022, 19, 250-264.	6.1	84
6	Recent Insights Into Mechanisms and Clinical Approaches to Electrical Storm. <i>Canadian Journal of Cardiology</i> , 2022, 38, 439-453.	0.8	14
7	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, , CIRCEP121010462.	2.1	3
8	Digital Technologies: Revolutionizing Cardiovascular Medicine and Reshaping the World. <i>Canadian Journal of Cardiology</i> , 2022, 38, 142-144.	0.8	0
9	Atrial fibrillation in heart failure: A practical approach for the clinician. <i>Canadian Journal of Cardiology</i> , 2022, , .	0.8	0
10	Understanding, Predicting, Preventing, and Treating Ventricular Arrhythmias: Pushing Sudden Death Into Overtime. <i>Canadian Journal of Cardiology</i> , 2022, 38, 414-417.	0.8	3
11	PO-616-07 THE ROLE OF CELLULAR SENESENCE IN ATRIAL FIBRILLATION. <i>Heart Rhythm</i> , 2022, 19, S113-S114.	0.3	0
12	Inflammasome Signaling in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2349-2366.	1.2	37
13	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. <i>Cardiovascular Research</i> , 2021, 117, 1776-1789.	1.8	38
14	Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling. <i>Cardiovascular Research</i> , 2021, 117, 462-471.	1.8	16
15	Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. <i>European Heart Journal</i> , 2021, 42, 532-540.	1.0	46
16	Postoperative Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 123-132.	0.7	12
17	Biomarkers in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 221-233.	0.7	19
18	Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 25-35.	0.7	51

#	ARTICLE	IF	CITATIONS
19	New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation. <i>Cardiovascular Research</i> , 2021, 117, 1645-1661.	1.8	24
20	Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it. <i>Cardiovascular Research</i> , 2021, 117, 1616-1631.	1.8	31
21	Sleep Apnea and Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 87-94.	0.7	21
22	Risk Factors in Atrial Fibrillation: Appraisal of Atrial Fibrillation Risk Stratification. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, xix-xx.	0.7	1
23	Inositol Trisphosphate Receptors and Nuclear Calcium in Atrial Fibrillation. <i>Circulation Research</i> , 2021, 128, 619-635.	2.0	20
24	Computational models of atrial fibrillation: achievements, challenges, and perspectives for improving clinical care. <i>Cardiovascular Research</i> , 2021, 117, 1682-1699.	1.8	47
25	Finding a new job: glutamate signaling acts in atrial cardiomyocytes. <i>Cell Research</i> , 2021, 31, 943-944.	5.7	1
26	One Ring to Rule Them All: Continuous Monitoring of Patients With Secondary Atrial Fibrillation Points to a Unifying Underlying Mechanism. <i>Canadian Journal of Cardiology</i> , 2021, 37, 686-689.	0.8	7
27	Cohesin-protein Shugoshin-1 controls cardiac automaticity via HCN4 pacemaker channel. <i>Nature Communications</i> , 2021, 12, 2551.	5.8	7
28	Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. <i>Cardiovascular Research</i> , 2021, 117, 1609-1611.	1.8	5
29	A computational model of pig ventricular cardiomyocyte electrophysiology and calcium handling: Translation from pig to human electrophysiology. <i>PLoS Computational Biology</i> , 2021, 17, e1009137.	1.5	3
30	Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1607-1618.	0.8	48
31	Ageing, comorbidities, and the complex determinants of atrial fibrillation in athletes. <i>European Heart Journal</i> , 2021, 42, 3526-3528.	1.0	4
32	Does gut microbiota affect atrial rhythm? Causalities and speculations. <i>European Heart Journal</i> , 2021, 42, 3521-3525.	1.0	23
33	Electrophysiological engineering of heart-derived cells with calcium-dependent potassium channels improves cell therapy efficacy for cardioprotection. <i>Nature Communications</i> , 2021, 12, 4963.	5.8	5
34	Transcriptomic Profiling of Canine Atrial Fibrillation Models After One Week of Sustained Arrhythmia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009887.	2.1	6
35	Atrial-Specific LKB1 Knockdown Represents a Novel Mouse Model of Atrial Cardiomyopathy With Spontaneous Atrial Fibrillation. <i>Circulation</i> , 2021, 144, 909-912.	1.6	10
36	Cardiac Na/Ca Exchange Suppression: A Late-Breaking Knockout Story Showing That There Is No Free Lunch. <i>Journal of the American Heart Association</i> , 2021, 10, e022512.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Understanding the molecular events preceding and leading to atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 2126-2127.	0.3	1
38	Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation. <i>Circulation Research</i> , 2021, 129, 804-820.	2.0	18
39	Fish Oil Supplements May Increase the Risk for Atrial Fibrillation: What Does This Mean?. <i>Circulation</i> , 2021, 144, 1991-1994.	1.6	4
40	Editorial Commentary: Obesity, body composition and atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 212-214.	2.3	3
41	Sex as a Key Variable in Predicting Cardiovascular Outcomes: Rapidly Evolving Knowledge but Much More Needed. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1-3.	0.8	4
42	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2179-2180.	1.2	0
43	Comparison of Atrial Remodeling Caused by Sustained Atrial Flutter Versus Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 374-388.	1.2	18
44	Association of Atrial Fibrillation Episode Duration With Arrhythmia Recurrence Following Ablation. <i>JAMA Network Open</i> , 2020, 3, e208748.	2.8	31
45	Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation. <i>Circulation Research</i> , 2020, 127, 1036-1055.	2.0	152
46	In Memoriam—Martial G. Bourassa (1931-2020). <i>Canadian Journal of Cardiology</i> , 2020, 36, 1562-1563.	0.8	0
47	The Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: A Look Back Over the Last 10 Years and a Look Forward. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1839-1842.	0.8	6
48	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1847-1948.	0.8	313
49	Electrophysiological Effects of Atrial Epicardial Adipose Tissue. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1212-1214.	1.2	6
50	Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. <i>Nature</i> , 2020, 587, 460-465.	13.7	55
51	Pulmonary Vein Stenosis After Atrial Fibrillation Ablation: Insights From the ADVICE Trial. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1965-1974.	0.8	14
52	Do Atrial Fibrillation—Promoting Gene Variants Act by Enhancing Atrial Remodeling?. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1522-1524.	1.3	1
53	Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy. <i>Circulation Research</i> , 2020, 127, 51-72.	2.0	222
54	Prevalence and clinical impact of spontaneous and adenosine-induced pulmonary vein reconnection in the Contact-Force vs. Cryoballoon Atrial Fibrillation Ablation (CIRCA-DOSE) study. <i>Heart Rhythm</i> , 2020, 17, 897-904.	0.3	7

#	ARTICLE	IF	CITATIONS
55	Physical activity and atrial fibrillation risk: itâ€™s complicated; and sex is critical. <i>European Heart Journal</i> , 2020, 41, 1487-1489.	1.0	10
56	A Focus on COVID-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients. <i>Canadian Journal of Cardiology</i> , 2020, 36, 787-788.	0.8	0
57	Linking cellular energy state to atrial fibrillation pathogenesis: Potential role of adenosine monophosphate-activated protein kinase. <i>Heart Rhythm</i> , 2020, 17, 1398-1404.	0.3	12
58	M/M/Infinity Birth-Death Processes â€” A Quantitative Representational Framework to Summarize and Explain Phase Singularity and Wavelet Dynamics in Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2020, 11, 616866.	1.3	14
59	Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation-remodeled hearts. <i>JCI Insight</i> , 2020, 5, .	2.3	28
60	Binge Alcohol Exposure Triggers Atrial Fibrillation Through T-Type Ca ²⁺ Channel Upregulation via Protein Kinase C (PKC) / Glycogen Synthesis Kinase 3 β (GSK3 β) / Nuclear Factor of Activated T-Cells (NFAT) Signaling- An Experimental Account of Holiday Heart Syndrome â€•. <i>Circulation Journal</i> , 2020, 84, 1931-1940.	0.7	11
61	Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling. <i>Cardiovascular Research</i> , 2019, 115, 94-106.	1.8	34
62	The Inability of the Choroid to Revascularize in Oxygen-Induced Retinopathy Results from Increased p53/miR-Let-7b Activity. <i>American Journal of Pathology</i> , 2019, 189, 2340-2356.	1.9	7
63	Notes From Cardiology Clinic: Medicine Is More Than Just Pills, Procedures, and Devices. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1263-1264.	0.8	0
64	Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1332-1347.	1.2	72
65	Role of the lysyl oxidase enzyme family in cardiac function and disease. <i>Cardiovascular Research</i> , 2019, 115, 1820-1837.	1.8	30
66	Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF- β 2 Signaling and Epigenomics. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 411-431.	2.3	11
67	An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. <i>Cardiovascular Research</i> , 2019, 115, 1975-1985.	1.8	14
68	Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. <i>Europace</i> , 2019, 21, 1261-1269.	0.7	21
69	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1069-1077.	0.8	27
70	Computational models of the atrial fibrillation substrate: can they explain post-ablation recurrences and help to prevent them. <i>Cardiovascular Research</i> , 2019, 115, 1681-1683.	1.8	1
71	Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA2DS2-VASc and Support for CHADS-65. <i>Canadian Journal of Cardiology</i> , 2019, 35, 547-549.	0.8	0
72	The Canadian Journal of Cardiology: Open and Growing. <i>Canadian Journal of Cardiology</i> , 2019, 35, 133-137.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Postoperative atrial fibrillation: mechanisms, manifestations and management. <i>Nature Reviews Cardiology</i> , 2019, 16, 417-436.	6.1	296
74	Postoperative Atrial Fibrillation After Noncardiac Surgery: Maybe Not So Benign After All. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1423-1425.	0.8	4
75	Renewal Theory as a Universal Quantitative Framework to Characterize Phase Singularity Regeneration in Mammalian Cardiac Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007569.	2.1	35
76	Role of autonomic nervous system in atrial fibrillation. <i>International Journal of Cardiology</i> , 2019, 287, 181-188.	0.8	95
77	Clarity and controversy around rate control in AF, the orphan child in AF therapeutics. <i>International Journal of Cardiology</i> , 2019, 287, 189-194.	0.8	1
78	Natriuretic peptide receptors and atrial-selective fibrosis: potential role in atrial fibrillation. <i>Cardiovascular Research</i> , 2019, 115, 258-260.	1.8	1
79	Translational Challenges in Atrial Fibrillation. <i>Circulation Research</i> , 2018, 122, 752-773.	2.0	131
80	Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells. <i>Journal of Physiology</i> , 2018, 596, 2359-2379.	1.3	16
81	Response by Lau et al to Letters Regarding Article, "Modifiable Risk Factors and Atrial Fibrillation". <i>Circulation</i> , 2018, 137, 1534-1535.	1.6	1
82	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Europace</i> , 2018, 20, e1-e160.	0.7	767
83	Electrical coupling between cardiomyocytes and fibroblasts: experimental testing of a challenging and important concept. <i>Cardiovascular Research</i> , 2018, 114, 349-352.	1.8	30
84	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Europace</i> , 2018, 20, 157-208.	0.7	375
85	Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment. <i>JAMA Cardiology</i> , 2018, 3, 532.	3.0	252
86	Atrial Infarction-Induced Spontaneous Focal Discharges and Atrial Fibrillation in Sheep. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005659.	2.1	23
87	Aging and Protein Kinase Activation. <i>Circulation Research</i> , 2018, 122, 799-801.	2.0	7
88	The Molecular Pathophysiology of Atrial Fibrillation. , 2018, , 396-408.		1
89	Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2018, 9, 1383.	1.3	77
90	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1371-1392.	0.8	195

#	ARTICLE	IF	CITATIONS
91	Catheter ablation of atrial fibrillation and outcomes in heart failure patients: seeking the treasure in the CASTLE. <i>Cardiovascular Research</i> , 2018, 114, e50-e52.	1.8	1
92	Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 2227-2242.	1.6	376
93	Mechanisms and Clinical Significance of Arrhythmia-Induced Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1449-1460.	0.8	30
94	Taking the Pulse of Atrial Fibrillation: A Practical Approach to Rate Control. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1526-1530.	0.8	7
95	Prof Niels Voigt talks to Prof Stanley Nattel about advances in atrial fibrillation research and career insights. <i>Cardiovascular Research</i> , 2018, 114, e65-e65.	1.8	0
96	Age as a Critical Determinant of Atrial Fibrillation: A Two-sided Relationship. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1396-1406.	0.8	36
97	Application of kinomic array analysis to screen for altered kinases in atrial fibrillation remodeling. <i>Heart Rhythm</i> , 2018, 15, 1708-1716.	0.3	5
98	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. <i>Heart Rhythm</i> , 2017, 14, e3-e40.	0.3	442
99	MicroRNA-135a regulates sodium-calcium exchanger gene expression and cardiac electrical activity. <i>Heart Rhythm</i> , 2017, 14, 739-748.	0.3	13
100	Aortic Vascular Calcification: Cholesterol Lowering Does Not Reduce Progression in Patients With Familial Hypercholesterolemia or Does It?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 594-596.	0.8	6
101	Intracellular Angiotensin II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	43
102	Rate-Dependent Role of I _{Kur} in Human Atrial Repolarization and Atrial Fibrillation Maintenance. <i>Biophysical Journal</i> , 2017, 112, 1997-2010.	0.2	18
103	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Heart Rhythm</i> , 2017, 14, e275-e444.	0.3	1,671
104	Atrial Fibrillation and Body Composition. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2498-2501.	1.2	19
105	Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 425-435.	1.3	290
106	Characterization of Sgo1 expression in developing and adult mouse. <i>Gene Expression Patterns</i> , 2017, 25-26, 36-45.	0.3	7
107	Controversies About Atrial Fibrillation Mechanisms. <i>Circulation Research</i> , 2017, 120, 1396-1398.	2.0	76
108	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 965-976.	0.8	89

#	ARTICLE	IF	CITATIONS
109	Demystifying rotors and their place in clinical translation of atrial fibrillation mechanisms. <i>Nature Reviews Cardiology</i> , 2017, 14, 509-520.	6.1	72
110	Endoplasmic Reticulum Stress Is Associated With Autophagy and Cardiomyocyte Remodeling in Experimental and Human Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	87
111	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Journal of Arrhythmia</i> , 2017, 33, 369-409.	0.5	348
112	Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1517-1519.	0.8	2
113	Basic Electrophysiology. <i>Cardiovascular Medicine</i> , 2017, , 1-13.	0.0	0
114	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 1-55.	0.6	83
115	A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1577-1586.	0.8	16
116	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Heart Rhythm</i> , 2017, 14, e445-e494.	0.3	135
117	Allele-Specific Gene Silencing. <i>Circulation Research</i> , 2017, 121, 480-482.	2.0	2
118	Dataset of Sgo1 expression in cardiac, gastrointestinal, hepatic and neuronal tissue in mouse. <i>Data in Brief</i> , 2017, 13, 731-737.	0.5	5
119	Atrial Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 756-765.	1.2	166
120	JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. <i>Cardiovascular Research</i> , 2017, 113, 310-320.	1.8	52
121	Modifiable Risk Factors and Atrial Fibrillation. <i>Circulation</i> , 2017, 136, 583-596.	1.6	451
122	Dysfunction of Myosin Lightâ€Chain 4 (MYL4) Leads to Heritable Atrial Cardiomyopathy With Electrical, Contractile, and Structural Components: Evidence From Geneticallyâ€Engineered Rats. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	52
123	T-tubular collagen: a new player in mechanosensing and disease?. <i>Cardiovascular Research</i> , 2017, 113, 839-840.	1.8	4
124	Close connections between contraction and rhythm: a new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us. <i>European Heart Journal</i> , 2017, 38, 35-37.	1.0	20
125	Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw. <i>Canadian Journal of Cardiology</i> , 2017, 33, 283-286.	0.8	34
126	Metabolic Considerations in Atrial Fibrillationâ€â€• Mechanistic Insights and Therapeutic Opportunities â€. <i>Circulation Journal</i> , 2017, 81, 1749-1757.	0.7	48

#	ARTICLE	IF	CITATIONS
127	Computational models of atrial cellular electrophysiology and calcium handling, and their role in atrial fibrillation. <i>Journal of Physiology</i> , 2016, 594, 537-553.	1.3	54
128	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. <i>Europace</i> , 2016, 18, 1455-1490.	0.7	471
129	The pioneering work of George Mines on cardiac arrhythmias: groundbreaking ideas that remain influential in contemporary cardiac electrophysiology. <i>Journal of Physiology</i> , 2016, 594, 2377-2386.	1.3	9
130	A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominant-negative mutation of the <i>KCNE1</i> gene. <i>British Journal of Pharmacology</i> , 2016, 173, 2046-2061.	2.7	38
131	An Emerging Malignant Arrhythmia Epidemic Due to Loperamide Abuse. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 790-792.	1.3	5
132	Potassium Channel Remodeling in Heart Disease. <i>Cardiac Electrophysiology Clinics</i> , 2016, 8, 337-347.	0.7	5
133	Dronedronarone. <i>Cardiac Electrophysiology Clinics</i> , 2016, 8, 453-465.	0.7	13
134	How does fibrosis promote atrial fibrillation persistence: <i>in silico</i> findings, clinical observations, and experimental data. <i>Cardiovascular Research</i> , 2016, 110, 295-297.	1.8	31
135	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. <i>Journal of Arrhythmia</i> , 2016, 32, 247-278.	0.5	92
136	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1170-1185.	0.8	243
137	Cardiac Potassium Channel Disorders: From Basics to Clinics. <i>Cardiac Electrophysiology Clinics</i> , 2016, 8, xv-xvi.	0.7	0
138	Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2016, 13, 575-590.	6.1	128
139	Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	109
140	Direct Effects of Activation and Inhibition of the Coagulation System on the Atrial Fibrillation Substrate. <i>JACC Basic To Translational Science</i> , 2016, 1, 340-343.	1.9	2
141	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16016.	18.1	185
142	Deciphering the fundamental mechanisms of atrial fibrillation: a quest for over a century. <i>Cardiovascular Research</i> , 2016, 109, 465-466.	1.8	7
143	Advances in drug, ablation, and device therapy for cardiac arrhythmias. <i>Nature Reviews Cardiology</i> , 2016, 13, 67-68.	6.1	6
144	The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. <i>Cardiovascular Research</i> , 2016, 109, 467-479.	1.8	166

#	ARTICLE	IF	CITATIONS
145	Caged ligands to study the role of intracellular GPCRs. <i>Methods</i> , 2016, 92, 72-77.	1.9	15
146	Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. <i>European Heart Journal</i> , 2016, 37, 640-650.	1.0	50
147	Role of Inflammation in Atrial Fibrillation Pathophysiology and Management. <i>Circulation Journal</i> , 2015, 79, 495-502.	0.7	345
148	The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 432-440.	0.8	15
149	Pulmonary vein exit block despite recovery of entry conduction during redo-ablation for atrial fibrillation. <i>Europace</i> , 2015, 17, 752-752.	0.7	3
150	Modeling the Aging Heart: From Local Respiratory Defects to Global Rhythm Disturbances. <i>Cell Metabolism</i> , 2015, 21, 662-663.	7.2	1
151	Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 769-782.	0.6	5
152	Innovative Therapeutics for Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 409-411.	0.8	1
153	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1207-1218.	0.8	43
154	Results-Based Accountability for Cardiovascular Epidemiology Research by the National Heart, Lung, and Blood Institute. <i>Circulation</i> , 2015, 132, 1949-1952.	1.6	0
155	Canadian Cardiovascular Society 2014 Algorithm for Anticoagulation Therapy in Atrial Fibrillation Debated. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1-2.	0.8	4
156	Changes in the Atrial Transcriptome and Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 5-7.	2.1	11
157	Fibroblast Inward-Rectifier Potassium Current Upregulation in Profibrillatory Atrial Remodeling. <i>Circulation Research</i> , 2015, 116, 836-845.	2.0	79
158	Targeting MicroRNA-208a to Suppress Adverse Postmyocardial Infarction Remodelling Related to RNA Activation of Endoglin Gene Expression. <i>Canadian Journal of Cardiology</i> , 2015, 31, 591-592.	0.8	5
159	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 105-115.	1.3	63
160	Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. <i>Lancet, The</i> , 2015, 386, 672-679.	6.3	188
161	Wavelet analysis of cardiac optical mapping data. <i>Computers in Biology and Medicine</i> , 2015, 65, 243-255.	3.9	17
162	Loss of Cardiomyocyte Integrin-Linked Kinase Produces an Arrhythmogenic Cardiomyopathy in Mice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 921-932.	2.1	21

#	ARTICLE	IF	CITATIONS
163	Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling. <i>Journal of the American College of Cardiology</i> , 2015, 66, 47-58.	1.2	75
164	Nestin is a Marker of Lung Remodeling Secondary to Myocardial Infarction and Type I Diabetes in the Rat. <i>Journal of Cellular Physiology</i> , 2015, 230, 170-179.	2.0	19
165	The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 973-981.	1.4	2
166	Potassium Channel Blockade Enhances Atrial Fibrillationâ€“Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade. <i>Circulation</i> , 2015, 132, 2203-2211.	1.6	41
167	Photoreleasable ligands to study intracrine angiotensin II signalling. <i>Journal of Physiology</i> , 2015, 593, 521-539.	1.3	16
168	MicroRNAs and atrial fibrillation: mechanisms and translational potential. <i>Nature Reviews Cardiology</i> , 2015, 12, 80-90.	6.1	116
169	Isolation and Study of Cardiac Nuclei from Canine Myocardium and Adult Ventricular Myocytes. <i>Methods in Molecular Biology</i> , 2015, 1234, 69-80.	0.4	5
170	Regional Ion Channel Gene Expression Heterogeneity and Ventricular Fibrillation Dynamics in Human Hearts. <i>PLoS ONE</i> , 2014, 9, e82179.	1.1	21
171	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1114-1130.	0.8	382
172	Ryanodine Receptorâ€“Mediated Calcium Leak Drives Progressive Development of an Atrial Fibrillation Substrate in a Transgenic Mouse Model. <i>Circulation</i> , 2014, 129, 1276-1285.	1.6	160
173	Calcium-dependent potassium channels in the heart: clarity and confusion. <i>Cardiovascular Research</i> , 2014, 101, 185-186.	1.8	9
174	N-type calcium channel blockade: a new approach to preventing sudden cardiac death?. <i>Cardiovascular Research</i> , 2014, 104, 1-2.	1.8	4
175	Activation of Histone Deacetylase-6 Induces Contractile Dysfunction Through Derailment of β -Tubulin Proteostasis in Experimental and Human Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 346-358.	1.6	118
176	Role of Small-Conductance Calcium-Activated Potassium Channels in Atrial Electrophysiology and Fibrillation in the Dog. <i>Circulation</i> , 2014, 129, 430-440.	1.6	153
177	Pulmonary vein isolation using â€œcontact forceâ€•ablation: The effect on dormant conduction and long-term freedom from recurrent atrial fibrillationâ€”A prospective study. <i>Heart Rhythm</i> , 2014, 11, 1919-1924.	0.3	144
178	New Directions in Cardiac Arrhythmia Management: Present Challenges and Future Solutions. <i>Canadian Journal of Cardiology</i> , 2014, 30, S420-S430.	0.8	31
179	A Look Into the Future of Cardiology: Perspectives From the Montreal Heart Institute. <i>Canadian Journal of Cardiology</i> , 2014, 30, S399-S400.	0.8	0
180	Inefficacy of a Highly Selective Tâ€“Type Calcium Channel Blocker in Preventing Atrial Fibrillation Related Remodeling. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 531-536.	0.8	3

#	ARTICLE	IF	CITATIONS
181	Atrial Ectopic Activity in Long-Standing Persistent Atrial Fibrillation: An Unanticipated Potentially Important Role?. Canadian Journal of Cardiology, 2014, 30, 1496-1497.	0.8	0
182	Atrial Fibrillation Compendium. Circulation Research, 2014, 114, 1447-1452.	2.0	30
183	The Molecular Pathophysiology of Atrial Fibrillation. , 2014, , 449-458.		1
184	Reply. Journal of the American College of Cardiology, 2014, 63, 89-90.	1.2	1
185	Lone Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 1715-1723.	1.2	177
186	Atrial Remodeling and Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 2335-2345.	1.2	544
187	Role of the Autonomic Nervous System in Atrial Fibrillation. Circulation Research, 2014, 114, 1500-1515.	2.0	578
188	Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression. Circulation Research, 2014, 114, 1483-1499.	2.0	530
189	Fibroblast Electrical Remodeling in Heart Failure and Potential Effects on Atrial Fibrillation. Biophysical Journal, 2014, 107, 2444-2455.	0.2	38
190	Atrial Fibrillation Promotion With Long-Term Repetitive Obstructive Sleep Apnea in a Rat Model. Journal of the American College of Cardiology, 2014, 64, 2013-2023.	1.2	172
191	Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. Journal of Molecular and Cellular Cardiology, 2014, 77, 113-124.	0.9	47
192	Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: Potential significance in arrhythmogenesis and antiarrhythmic therapy. Heart Rhythm, 2014, 11, 2092-2100.	0.3	25
193	Serum Uric Acid Concentration and Left Atrial Thrombus: Biomarker, Pathophysiological Indicator, or Innocent Bystander?. Canadian Journal of Cardiology, 2014, 30, 1259-1261.	0.8	1
194	Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation, and Oxidative Stress. Journal of the American College of Cardiology, 2014, 64, 1441-1448.	1.2	76
195	Cardiac fibrillation "challenges and evolving solutions. Nature Reviews Cardiology, 2014, 11, 626-627.	6.1	4
196	Cellular and Molecular Mechanisms of Atrial Arrhythmogenesis in Patients With Paroxysmal Atrial Fibrillation. Circulation, 2014, 129, 145-156.	1.6	386
197	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. Journal of the American Heart Association, 2014, 3, .	1.6	39
198	The Clinical Profile and Pathophysiology of Atrial Fibrillation. Circulation Research, 2014, 114, 1453-1468.	2.0	899

#	ARTICLE	IF	CITATIONS
199	F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 667-677.	1.4	7
200	Sex Differences in Cardiac Electrophysiology and Clinical Arrhythmias: Epidemiology, Therapeutics, and Mechanisms. <i>Canadian Journal of Cardiology</i> , 2014, 30, 783-792.	0.8	109
201	MicroRNA Regulation and Cardiac Calcium Signaling. <i>Circulation Research</i> , 2014, 114, 689-705.	2.0	117
202	Atrial Fibrillation Ablation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 823-831.	1.2	79
203	Exchange Protein Directly Activated by cAMP Mediates Slow Delayed-Rectifier Current Remodeling by Sustained I^2 -Adrenergic Activation in Guinea Pig Hearts. <i>Circulation Research</i> , 2014, 114, 993-1003.	2.0	44
204	Increasing Appreciation for the Role of Single-Pill Combinations for the Prevention of Atherosclerotic Disease: A Pro-Polypill Polemic. <i>Canadian Journal of Cardiology</i> , 2014, 30, 517-519.	0.8	2
205	Canadian Journal of Cardiology in 2014: From Percutaneous Intervention to Regenerative Medicine. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1-2.	0.8	10
206	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014, 35, 1448-1456.	1.0	190
207	Disease and region-related cardiac fibroblast potassium current variations and potential functional significance. <i>Cardiovascular Research</i> , 2014, 102, 487-496.	1.8	17
208	Cholinergic and Constitutive Regulation of Atrial Potassium Channel. , 2014, , 383-391.		0
209	Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca^{2+} in adult cardiac myocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 62, 189-202.	0.9	43
210	Electrical storm: recent pathophysiological insights and therapeutic consequences. <i>Basic Research in Cardiology</i> , 2013, 108, 336.	2.5	32
211	Management of Atrial Fibrillation in the Year 2033: New Concepts, Tools, and Applications Leading to Personalized Medicine. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1141-1146.	0.8	33
212	Paroxysmal Atrial Fibrillation and Pulmonary Veins: Relationships Between Clinical Forms and Automatic Versus Re-entrant Mechanisms. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1147-1149.	0.8	35
213	Region-specific gene expression profiles in the left atria of patients with valvular atrial fibrillation. <i>Heart Rhythm</i> , 2013, 10, 383-391.	0.3	57
214	Anticoagulation for Atrial Fibrillation: State of the Art and Recommendations for a Quickly Moving Target. <i>Canadian Journal of Cardiology</i> , 2013, 29, S1-S3.	0.8	0
215	Unique Quantitative Trait Loci in Synergy Permanently Improve Diastolic Dysfunction. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1302-1309.	0.8	2
216	Corticosteroid use during pulmonary vein isolation is associated with a higher prevalence of dormant pulmonary vein conduction. <i>Heart Rhythm</i> , 2013, 10, 1569-1575.	0.3	16

#	ARTICLE	IF	CITATIONS
217	Canadian Journal of Cardiology January 2013: Genetics and More. Canadian Journal of Cardiology, 2013, 29, 1-2.	0.8	11
218	Phosphodiesterase-2 Is Up-Regulated in Human Failing Hearts and Blunts β^2 -Adrenergic Responses in Cardiomyocytes. Journal of the American College of Cardiology, 2013, 62, 1596-1606.	1.2	115
219	Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. Journal of Physiology, 2013, 591, 1409-1432.	1.3	120
220	MicroRNA29. Circulation, 2013, 127, 1466-1475.	1.6	222
221	Atrial Fibrillation Promotion by Endurance Exercise. Journal of the American College of Cardiology, 2013, 62, 68-77.	1.2	252
222	Regulation of cardiac nitric oxide signaling by nuclear β^2 -adrenergic and endothelin receptors. Journal of Molecular and Cellular Cardiology, 2013, 62, 58-68.	0.9	45
223	Late pulmonary vein reconnection: insights into mechanisms of atrial fibrillation recurrence after pulmonary vein isolation. Europace, 2013, 15, 1143-1143.	0.7	61
224	T-Type Calcium Current Contributes to Escape Automaticity and Governs the Occurrence of Lethal Arrhythmias After Atrioventricular Block in Mice. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 799-808.	2.1	19
225	Unique Cardiac Purkinje Fiber Transient Outward Current β^2 -Subunit Composition. Circulation Research, 2013, 112, 1310-1322.	2.0	77
226	Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Mediates the Differential Responsiveness of Atrial Versus Ventricular Fibroblasts to Transforming Growth Factor- β^2 . Circulation: Arrhythmia and Electrophysiology, 2013, 6, 790-798.	2.1	42
227	Pulmonary Vein Isolation Using a Pace-Capture-Guided Versus an Adenosine-Guided Approach. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1103-1108.	2.1	46
228	Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation. , 2013, , 333-352.		0
229	Adenosine Testing in Atrial Flutter Ablation: Unmasking of Dormant Conduction Across the Cavotricuspid Isthmus and Risk of Recurrence. Journal of Cardiovascular Electrophysiology, 2013, 24, 995-1001.	0.8	22
230	Rebuttal from Eduard Guasch and Stanley Nattel. Journal of Physiology, 2013, 591, 4947-4947.	1.3	0
231	CrossTalk proposal: Prolonged intense exercise training does lead to myocardial damage. Journal of Physiology, 2013, 591, 4939-4941.	1.3	17
232	Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. Journal of Physiology, 2013, 591, 4189-4206.	1.3	122
233	A Clinical Approach to Early Repolarization. Circulation, 2013, 127, 1620-1629.	1.6	38
234	Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes. American Journal of Physiology - Renal Physiology, 2013, 304, F849-F862.	1.3	12

#	ARTICLE	IF	CITATIONS
235	Combining distinctive and novel loci doubles BP reduction, reverses diastolic dysfunction and mitigates LV hypertrophy. <i>Journal of Hypertension</i> , 2013, 31, 927-935.	0.3	4
236	Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model. <i>PLoS ONE</i> , 2013, 8, e55427.	1.1	47
237	MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. <i>Journal of Clinical Investigation</i> , 2013, 123, 1939-1951.	3.9	232
238	Antiarrhythmic drugs and strategies. , 2013, , 272-331.		4
239	Transient Receptor Potential Canonical-3 Channel-Dependent Fibroblast Regulation in Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 2051-2064.	1.6	228
240	Atrial Fibrillation-Associated Remodeling Does Not Promote Atrial Thrombus Formation in Canine Models. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 1168-1175.	2.1	18
241	Enhanced Sarcoplasmic Reticulum Ca ²⁺ Leak and Increased Na ⁺ -Ca ²⁺ Exchanger Function Underlie Delayed Afterdepolarizations in Patients With Chronic Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 2059-2070.	1.6	523
242	AMP-Activated Protein Kinase. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 860-867.	2.1	38
243	Novel molecular targets for atrial fibrillation therapy. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 275-291.	21.5	170
244	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the E. Europace, 2012, 14, 528-606.	0.7	1,497
245	Calcium handling and atrial fibrillation. <i>Wiener Medizinische Wochenschrift</i> , 2012, 162, 287-291.	0.5	25
246	Inflammation and Biomarkers in Vascular Disease: Emerging Insights and Opportunities. <i>Canadian Journal of Cardiology</i> , 2012, 28, 616-618.	0.8	0
247	Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: A comparative multicenter study. <i>Heart Rhythm</i> , 2012, 9, 1025-1030.	0.3	63
248	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. <i>Heart Rhythm</i> , 2012, 9, 632-696.e21.	0.3	1,541
249	Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. <i>Heart Rhythm</i> , 2012, 9, 1409-1416.e1.	0.3	106
250	The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. <i>European Heart Journal</i> , 2012, 33, 1870-1877.	1.0	181
251	Hypoxia in early life is associated with lasting changes in left ventricular structure and function at maturity in the rat. <i>International Journal of Cardiology</i> , 2012, 156, 165-173.	0.8	13
252	Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE): Methods and Rationale. <i>Canadian Journal of Cardiology</i> , 2012, 28, 184-190.	0.8	54

#	ARTICLE	IF	CITATIONS
253	Canadian Journal of Cardiology: A Year of Change. Canadian Journal of Cardiology, 2012, 28, 5.	0.8	4
254	Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. Canadian Journal of Cardiology, 2012, 28, 125-136.	0.8	461
255	G protein-coupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. Journal of Physiology, 2012, 590, 1313-1330.	1.3	115
256	Triggering of cardiac arrhythmic events in long QT syndrome: lessons from funny bunnies. Journal of Physiology, 2012, 590, 1311-1312.	1.3	8
257	A proposal for new clinical concepts in the management of atrial fibrillation. American Heart Journal, 2012, 164, 292-302.e1.	1.2	47
258	In Silico Optimization of Atrial Fibrillation-Selective Sodium Channel Blocker Pharmacodynamics. Biophysical Journal, 2012, 102, 951-960.	0.2	25
259	Role for MicroRNA-21 in Atrial Profibrillatory Fibrotic Remodeling Associated With Experimental Postinfarction Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1027-1035.	2.1	161
260	Connexins and Atrial Fibrillation. Circulation, 2012, 125, 203-206.	1.6	69
261	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 171-257.	0.6	1,167
262	Adenosine and Atrial Arrhythmias: Exploring Electrophysiological Mechanisms <i>In Vivo</i> . PACE - Pacing and Clinical Electrophysiology, 2012, 35, 553-555.	0.5	5
263	Atrial Repolarization Alternans as a Path to Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2012, 23, 1013-1015.	0.8	18
264	Proarrhythmic Atrial Calcium Cycling in the Diseased Heart. Advances in Experimental Medicine and Biology, 2012, 740, 1175-1191.	0.8	13
265	Congestive Heart Failure Effects on Atrial Fibroblast Phenotype: Differences between Freshly-Isolated and Cultured Cells. PLoS ONE, 2012, 7, e52032.	1.1	32
266	Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training. Circulation, 2011, 123, 13-22.	1.6	394
267	Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovascular Research, 2011, 91, 420-428.	1.8	21
268	The role of pulmonary veins vs. autonomic ganglia in different experimental substrates of canine atrial fibrillation. Cardiovascular Research, 2011, 89, 825-833.	1.8	58
269	Reply to the Editor "Mechanoelectrical factors in M-cell debate. Heart Rhythm, 2011, 8, e2.	0.3	0
270	Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: A clinical-experimental correlation. Heart Rhythm, 2011, 8, 1426-1433.	0.3	52

#	ARTICLE	IF	CITATIONS
271	Resolving the M-cell debate: Why and how. Heart Rhythm, 2011, 8, 1293-1295.	0.3	22
272	Dronedaronone in Atrial Fibrillation â€” Jekyll and Hyde?. New England Journal of Medicine, 2011, 365, 2321-2322.	13.9	20
273	New insights into the molecular basis of atrial fibrillation: mechanistic and therapeutic implications. Cardiovascular Research, 2011, 89, 689-691.	1.8	25
274	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Canadian Journal of Cardiology, 2011, 27, 47-59.	0.8	112
275	From Guidelines to Bench: Implications of Unresolved Clinical Issues for Basic Investigations of Atrial Fibrillation Mechanisms. Canadian Journal of Cardiology, 2011, 27, 19-26.	0.8	49
276	A Proud Tradition and a New Beginning With a Theme Issue on Atrial Fibrillation. Canadian Journal of Cardiology, 2011, 27, 5-6.	0.8	0
277	A Focus on Hypertension: A Modest Condition of Enormous Significance. Canadian Journal of Cardiology, 2011, 27, 394-396.	0.8	0
278	Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovascular Research, 2011, 89, 744-753.	1.8	325
279	Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): Standardised reporting for model reproducibility, interoperability, and data sharing. Progress in Biophysics and Molecular Biology, 2011, 107, 4-10.	1.4	75
280	Therapy with omega-3 fatty acidsâ€”is the case closed?. Nature Reviews Cardiology, 2011, 8, 126-128.	6.1	5
281	Impact of tissue geometry on simulated cholinergic atrial fibrillation: A modeling study. Chaos, 2011, 21, 013108.	1.0	16
282	Response to Letters Regarding Article, â€œCardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Trainingâ€. Circulation, 2011, 124, .	1.6	0
283	Differential Protein Kinase C Isoform Regulation and Increased Constitutive Activity of Acetylcholine-Regulated Potassium Channels in Atrial Remodeling. Circulation Research, 2011, 109, 1031-1043.	2.0	93
284	Role of K _{ATP} Channels in the Maintenance of Ventricular Fibrillation in Cardiomyopathic Human Hearts. Circulation Research, 2011, 109, 1309-1318.	2.0	49
285	Mechanisms of Atrial Tachyarrhythmias Associated With Coronary Artery Occlusion in a Chronic Canine Model. Circulation, 2011, 123, 137-146.	1.6	151
286	Ca ²⁺ -Related Signaling and Protein Phosphorylation Abnormalities Play Central Roles in a New Experimental Model of Electrical Storm. Circulation, 2011, 123, 2192-2203.	1.6	57
287	Recent advances in the molecular pathophysiology of atrial fibrillation. Journal of Clinical Investigation, 2011, 121, 2955-2968.	3.9	480
288	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovascular Research, 2011, 92, 67-74.	1.8	84

#	ARTICLE	IF	CITATIONS
289	Transforming growth factor- β^2 and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. <i>Cardiovascular Research</i> , 2011, 91, 62-70.	1.8	62
290	Anthrax Lethal Factor Activates K ⁺ Channels To Induce IL-1 β Secretion in Macrophages. <i>Journal of Immunology</i> , 2011, 186, 5236-5243.	0.4	12
291	Interactions between cardiac fibrosis spatial pattern and ionic remodeling on electrical wave propagation. , 2011, 2011, 4669-72.		21
292	Atrial Fibrillation Pathophysiology. <i>Circulation</i> , 2011, 124, 2264-2274.	1.6	646
293	Familial Idiopathic Ventricular Fibrillation Linked to Chromosome 7q36 Harboring DPP6. <i>Journal of Arrhythmia</i> , 2011, 27, OP59_4.	0.5	0
294	Concealed Automaticity From an Island of Atrial Myocardium Post Cavotricuspid Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 1408-1409.	0.8	1
295	Exercise training, inflammation and heart failure: working out to cool down. <i>Journal of Physiology</i> , 2010, 588, 2525-2526.	1.3	5
296	Physiological versus pathological cardiac electrical remodelling: potential basis and relevance to clinical management. <i>Journal of Physiology</i> , 2010, 588, 4855-4856.	1.3	7
297	Sudden Cardio Arrest: When normal ECG variants turn lethal. <i>Nature Medicine</i> , 2010, 16, 646-647.	15.2	10
298	A high-fat diet increases risk of ventricular arrhythmia in female rats: enhanced arrhythmic risk in the absence of obesity or hyperlipidemia. <i>Journal of Applied Physiology</i> , 2010, 108, 933-940.	1.2	28
299	Multiple Potential Molecular Contributors to Atrial Hypocontractility Caused by Atrial Tachycardia Remodeling in Dogs. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 530-541.	2.1	112
300	Mechanisms by Which Adenosine Restores Conduction in Dormant Canine Pulmonary Veins. <i>Circulation</i> , 2010, 121, 963-972.	1.6	183
301	Nuclear-delimited Angiotensin Receptor-mediated Signaling Regulates Cardiomyocyte Gene Expression. <i>Journal of Biological Chemistry</i> , 2010, 285, 22338-22349.	1.6	97
302	Animal models for atrial fibrillation: clinical insights and scientific opportunities. <i>Europace</i> , 2010, 12, 160-172.	0.7	131
303	Role of constitutively active acetylcholine-mediated potassium current in atrial contractile dysfunction caused by atrial tachycardia remodelling. <i>Europace</i> , 2010, 12, 1490-1497.	0.7	10
304	Left-to-Right Atrial Inward Rectifier Potassium Current Gradients in Patients With Paroxysmal Versus Chronic Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 472-480.	2.1	204
305	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. <i>Heart Rhythm</i> , 2010, 7, 1862-1869.	0.3	50
306	Looking Into the Left Atrial Crystal Ball. <i>Journal of the American College of Cardiology</i> , 2010, 56, 579-581.	1.2	4

#	ARTICLE	IF	CITATIONS
307	Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1796-1802.	1.2	129
308	Clinical and Mechanistic Issues in Early Repolarization. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1177-1186.	1.2	89
309	Roles of the Left Atrial Roof and Pulmonary Veins in the Anatomic Substrate for Persistent Atrial Fibrillation and Ablation in a Canine Model. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1728-1736.	1.2	29
310	Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice. <i>Drugs</i> , 2010, 70, 573-603.	4.9	65
311	Ion-channel mRNA-expression profiling: Insights into cardiac remodeling and arrhythmic substrates. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 96-105.	0.9	33
312	Erratum to "Ion-channel mRNA-expression profiling: Insights into cardiac remodeling and arrhythmic substrates" [J. Mol. Cell. Cardiol. 48 (2010) 96-105]. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 1335-1339.	0.9	0
313	Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 639-646.	0.9	160
314	Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 851-863.	0.9	83
315	New antiarrhythmic drugs for treatment of atrial fibrillation. <i>Lancet</i> , The, 2010, 375, 1212-1223.	6.3	261
316	Voltage-Clamp-Based Methods for the Detection of Constitutively Active Acetylcholine-Gated IK,ACh Channels in the Diseased Heart. <i>Methods in Enzymology</i> , 2010, 484, 653-675.	0.4	17
317	Dormant pulmonary vein conduction unmasked by external electrical cardioversion. <i>Heart Rhythm</i> , 2010, 7, 1706-1707.	0.3	1
318	Mechanisms of lethal arrhythmias due to acute myocardial ischemia: Regional factors and challenges in sudden death prevention. <i>Heart Rhythm</i> , 2010, 7, 387-388.	0.3	0
319	Regulator of G-protein signalling 4 (RGS4) KO mice show increased susceptibility to atrial fibrillation. <i>FASEB Journal</i> , 2010, 24, 855.1.	0.2	1
320	Experimental and Theoretical Insights into Fundamental Mechanisms of Antiarrhythmic Drug Actions on Atrial Fibrillation: Prospects for Improved Pharmacotherapy. , 2009, , 52-60.		0
321	Transcriptional profiling of ion channel genes in Brugada syndrome and other right ventricular arrhythmogenic diseases. <i>European Heart Journal</i> , 2009, 30, 487-496.	1.0	47
322	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <i>Europace</i> , 2009, 11, 860-885.	0.7	104
323	Rate-dependence of atrial tachycardia effects on atrial refractoriness and atrial fibrillation maintenance. <i>Cardiovascular Research</i> , 2009, 81, 90-97.	1.8	24
324	Cardiac pathways distinguish two epistatic modules enacting BP quantitative trait loci and candidate gene analysis. <i>Hypertension Research</i> , 2009, 32, 631-637.	1.5	12

#	ARTICLE	IF	CITATIONS
325	Changes in Connexin Expression and the Atrial Fibrillation Substrate in Congestive Heart Failure. <i>Circulation Research</i> , 2009, 105, 1213-1222.	2.0	178
326	Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle. <i>Circulation</i> , 2009, 119, 1824-1831.	1.6	39
327	Ion Channel Subunit Expression Changes in Cardiac Purkinje Fibers. <i>Circulation Research</i> , 2009, 104, 1113-1122.	2.0	49
328	The Calcium/Calmodulin/Kinase System and Arrhythmogenic Afterdepolarizations in Bradycardia-Related Acquired Long-QT Syndrome. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 295-304.	2.1	58
329	Prevention of Atrial Fibrillation. <i>Circulation</i> , 2009, 119, 606-618.	1.6	446
330	Funny Current Downregulation and Sinus Node Dysfunction Associated With Atrial Tachyarrhythmia. <i>Circulation</i> , 2009, 119, 1576-1585.	1.6	123
331	Association of neonatal hypoxia with lasting changes in left ventricular gene expression: An animal model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 538-546.e1.	0.4	17
332	Calcium-activated potassium current: a novel ion channel candidate in atrial fibrillation. <i>Journal of Physiology</i> , 2009, 587, 1385-1386.	1.3	30
333	Fast and furious: new ways to think about, study and treat cardiac arrhythmias. <i>Journal of Physiology</i> , 2009, 587, 1383-1384.	1.3	0
334	Exercise training as a treatment for heart failure: potential mechanisms and clinical implications. <i>Journal of Physiology</i> , 2009, 587, 5011-5013.	1.3	11
335	Ventricular Proarrhythmic Effects of Atrial Fibrillation are Modulated by Depolarization and Repolarization Anomalies in Patients with Left Ventricular Dysfunction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 99-105.	0.5	11
336	Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 385-394.	0.9	96
337	Novel Approaches for Pharmacological Management of Atrial Fibrillation. <i>Drugs</i> , 2009, 69, 757-774.	4.9	69
338	Cell calcium, repolarization changes, and spontaneous postshock fibrillation in failing hearts: Causes of refrillation and electrical storm. <i>Heart Rhythm</i> , 2009, 6, 793-795.	0.3	1
339	Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. <i>Heart Rhythm</i> , 2009, 6, 1802-1809.	0.3	237
340	Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. <i>Heart Rhythm</i> , 2009, 6, 1465-1472.	0.3	25
341	Frequency-domain versus time-domain analysis: Optimizing complex fractionated atrial electrogram identification for atrial fibrillation ablation. <i>Heart Rhythm</i> , 2009, 6, 1483-1484.	0.3	0
342	Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: Evidence for clinically significant IKr-IKs β -subunit interaction. <i>Heart Rhythm</i> , 2009, 6, 1792-1801.	0.3	34

#	ARTICLE	IF	CITATIONS
343	G-protein signaling and arrhythmogenic atrial remodeling: Relevance to novel therapeutic targets in atrial fibrillation. <i>Heart Rhythm</i> , 2009, 6, 85-86.	0.3	7
344	Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. <i>Current Opinion in Cardiology</i> , 2009, 24, 50-55.	0.8	44
345	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference "research perspectives in AF"™. <i>European Heart Journal</i> , 2009, 30, 2969-2980.	1.0	173
346	Consequences of Atrial or Ventricular Tachypacing on the Heat Shock Proteins (HSP) level of Expression and Phosphorylation. <i>McGill Journal of Medicine</i> , 2009, 12, 34.	0.1	2
347	Case Studies with the Experts: Management Decisions in Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, S1-12; quiz S13-5.	0.8	5
348	Delayed rectifier potassium currents and the control of cardiac repolarization: Noble and Tsien 40 years after. <i>Journal of Physiology</i> , 2008, 586, 5849-5852.	1.3	7
349	Model systems for the discovery and development of antiarrhythmic drugs. <i>Progress in Biophysics and Molecular Biology</i> , 2008, 98, 328-339.	1.4	29
350	Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. <i>Heart Rhythm</i> , 2008, 5, 451-459.	0.3	104
351	Atrial-Selective Approaches for the Treatment of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2008, 51, 787-792.	1.2	80
352	Molecular basis of funny current (I _f) in normal and failing human heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 289-299.	0.9	158
353	Marked differences between atrial and ventricular gene-expression remodeling in dogs with experimental heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 821-831.	0.9	34
354	Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 685-693.	0.9	76
355	Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: Evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 707-708.	0.9	6
356	Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2008, 51, 802-809.	1.2	1,044
357	Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2667-2677.	13.9	1,421
358	Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF). <i>Canadian Journal of Cardiology</i> , 2008, 24, 709-713.	0.8	20
359	Cellular properties of C-terminal KCNH2 long QT syndrome mutations: Description and divergence from clinical phenotypes. <i>Heart Rhythm</i> , 2008, 5, 1159-1167.	0.3	8
360	Repolarization indices or calcium-current recovery/repolarization balance: What determines torsadogenesis?. <i>Heart Rhythm</i> , 2008, 5, 280-281.	0.3	1

#	ARTICLE	IF	CITATIONS
361	To the Editor's Response. Heart Rhythm, 2008, 5, 636-637.	0.3	0
362	Complex fractionated atrial electrograms: Can they be made simple?. Heart Rhythm, 2008, 5, 855-856.	0.3	1
363	Inward rectifier's funny current balance and spontaneous automaticity: Cautionary notes for biologic pacemaker development. Heart Rhythm, 2008, 5, 1318-1319.	0.3	4
364	Atrial Remodeling and Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 62-73.	2.1	897
365	Pulmonary Vein Region Ablation in Experimental Vagal Atrial Fibrillation. Circulation, 2008, 117, 470-477.	1.6	196
366	Atrial Structural Remodeling as an Antiarrhythmic Target. Journal of Cardiovascular Pharmacology, 2008, 52, 4-10.	0.8	57
367	Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovascular Research, 2008, 81, 491-499.	1.8	90
368	Effects of Heart Disease on Cardiac Ion Current Density Versus Current Amplitude. Circulation Research, 2008, 102, 1298-1300.	2.0	10
369	Differential Behaviors of Atrial Versus Ventricular Fibroblasts. Circulation, 2008, 117, 1630-1641.	1.6	231
370	Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovascular Research, 2008, 78, 422-428.	1.8	49
371	Calcium-Handling Abnormalities Underlying Atrial Arrhythmogenesis and Contractile Dysfunction in Dogs With Congestive Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 93-102.	2.1	239
372	Mechanisms of atrial fibrillation termination by rapidly unbinding Na ⁺ channel blockers: insights from mathematical models and experimental correlates. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1489-H1504.	1.5	63
373	Differential Interactions of Na ⁺ Channel Toxins with T-type Ca ²⁺ Channels. Journal of General Physiology, 2008, 132, 101-113.	0.9	19
374	Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovascular Research, 2008, 78, 63-70.	1.8	62
375	Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovascular Research, 2008, 79, 61-69.	1.8	48
376	Mechanisms Underlying Rate-Dependent Remodeling of Transient Outward Potassium Current in Canine Ventricular Myocytes. Circulation Research, 2008, 103, 733-742.	2.0	73
377	Cellular Signaling Underlying Atrial Tachycardia Remodeling of L-type Calcium Current. Circulation Research, 2008, 103, 845-854.	2.0	174
378	Feedback Remodeling of Cardiac Potassium Current Expression. Circulation, 2008, 118, 983-992.	1.6	88

#	ARTICLE	IF	CITATIONS
379	Calcium Handling Abnormalities in Atrial Fibrillation as a Target for Innovative Therapeutics. Journal of Cardiovascular Pharmacology, 2008, 52, 293-299.	0.8	100
380	Distinct genomic replacements from Lewis correct diastolic dysfunction, attenuate hypertension, and reduce left ventricular hypertrophy in Dahl salt-sensitive rats. Journal of Hypertension, 2008, 26, 1935-1943.	0.3	9
381	Evolving Developments in the Therapeutics of Atrial Fibrillation: Addressing an Unmet Need. Journal of Cardiovascular Pharmacology, 2008, 52, 1-3.	0.8	1
382	Atrial fibrillation: evidence for genetically determined disease. Current Opinion in Cardiology, 2008, 23, 176-183.	0.8	39
383	Cellular Electrophysiology and the Substrate for Atrial Fibrillation. , 2008, , 37-56.		1
384	Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation. , 2008, , 261-280.		1
385	Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation. Physiological Reviews, 2007, 87, 425-456.	13.1	752
386	Contrasting Gene Expression Profiles in Two Canine Models of Atrial Fibrillation. Circulation Research, 2007, 100, 425-433.	2.0	94
387	Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovascular Research, 2007, 74, 75-84.	1.8	144
388	The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy. Cardiovascular Research, 2007, 74, 104-113.	1.8	45
389	Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: A novel consideration in atrial remodeling. Cardiovascular Research, 2007, 76, 442-452.	1.8	136
390	Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling. Circulation, 2007, 116, 2101-2109.	1.6	130
391	Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management. Current Vascular Pharmacology, 2007, 5, 185-194.	0.8	21
392	Characterization of the cardiac KCNE1 gene promoter. Cardiovascular Research, 2007, 73, 82-91.	1.8	11
393	Adrenergic control of a constitutively active acetylcholine-regulated potassium current in canine atrial cardiomyocytes. Cardiovascular Research, 2007, 74, 406-415.	1.8	31
394	Changes in IK,ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovascular Research, 2007, 77, 35-43.	1.8	91
395	Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block. Europace, 2007, 9, 869-874.	0.7	44
396	Effects of Resveratrol (trans-3,5,4-Trihydroxystilbene) Treatment on Cardiac Remodeling following Myocardial Infarction. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 916-923.	1.3	44

#	ARTICLE	IF	CITATIONS
397	Model-Dependent Effects of the Gap Junction Conductionâ€“Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. <i>Circulation</i> , 2007, 115, 310-318.	1.6	127
398	Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 43, 223-229.	0.9	141
399	The heart on a chip: The role of realistic mathematical models of cardiac electrical activity in understanding and treating cardiac arrhythmias. <i>Heart Rhythm</i> , 2007, 4, 779-780.	0.3	3
400	Protein kinase C, connexin43, and ischemic preconditioning: Complex interactions of potential importance for controlling arrhythmias. <i>Heart Rhythm</i> , 2007, 4, 1194-1195.	0.3	0
401	Teasing out circadian variability in heart rate turbulence: A new approach to detecting biorhythms underlying cardiac function. <i>Heart Rhythm</i> , 2007, 4, 301-303.	0.3	1
402	Pulmonary vein reentryâ€“Properties and size matter: Insights from a computational analysis. <i>Heart Rhythm</i> , 2007, 4, 1553-1562.	0.3	83
403	Pharmacological elimination of motion artifacts during optical imaging of cardiac tissues: Is blebbistatin the answer?. <i>Heart Rhythm</i> , 2007, 4, 627-628.	0.3	11
404	Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. <i>Journal of Physiology</i> , 2007, 582, 675-693.	1.3	434
405	Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. <i>Journal of Physiology</i> , 2007, 582, 1205-1217.	1.3	81
406	Atrial tachycardia induces remodelling of muscarinic receptors and their coupled potassium currents in canine left atrial and pulmonary vein cardiomyocytes. <i>British Journal of Pharmacology</i> , 2007, 152, 1021-1032.	2.7	17
407	The Use of Cardiovascular Drugs: Pharmacological Principles. , 2007, , 35-39.		0
408	P3-17. <i>Heart Rhythm</i> , 2006, 3, S183.	0.3	13
409	Controversies in atrial fibrillation. <i>Lancet, The</i> , 2006, 367, 262-272.	6.3	169
410	Controversies in cardiology â€“ Authors' reply. <i>Lancet, The</i> , 2006, 367, 1315-1316.	6.3	5
411	Sex-based transmural differences in cardiac repolarization and ionic-current properties in canine left ventricles. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H570-H580.	1.5	69
412	Ventricular tachyarrhythmia induction by strong cardiac shocks: Can understanding underlying mechanisms lead to improved prevention of defibrillator failure?. <i>Heart Rhythm</i> , 2006, 3, 596-597.	0.3	0
413	P3-7. <i>Heart Rhythm</i> , 2006, 3, S180.	0.3	0
414	Inappropriate sinus tachycardia and beta-receptor autoantibodies: A mechanistic breakthrough?. <i>Heart Rhythm</i> , 2006, 3, 1187-1188.	0.3	13

#	ARTICLE	IF	CITATIONS
415	Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 173-184.	0.9	71
416	Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 123-132.	0.8	43
417	Preoperative Atrial Cardiomyocyte Ionic Currents and Postoperative AF: Important Insights Into What Is Not the Mechanism. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 1239-1241.	0.8	3
418	Innovative approaches to anti-arrhythmic drug therapy. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 1034-1049.	21.5	175
419	Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. <i>European Heart Journal</i> , 2006, 27, 512-518.	1.0	290
420	Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. <i>Cardiovascular Research</i> , 2006, 69, 865-875.	1.8	96
421	Comparison of Ca ²⁺ -handling properties of canine pulmonary vein and left atrial cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2290-H2300.	1.5	39
422	Potassium Channel Subunit Remodeling in Rabbits Exposed to Long-Term Bradycardia or Tachycardia. <i>Circulation</i> , 2006, 113, 345-355.	1.6	133
423	Induction of Heat Shock Response Protects the Heart Against Atrial Fibrillation. <i>Circulation Research</i> , 2006, 99, 1394-1402.	2.0	158
424	Properties of a Time-Dependent Potassium Current in Pig Atrium: Evidence for a Role of Kv1.5 in Repolarization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 898-906.	1.3	17
425	Involvement of lipid rafts and caveolae in cardiac ion channel function. <i>Cardiovascular Research</i> , 2006, 69, 798-807.	1.8	181
426	Kir3-Based Inward Rectifier Potassium Current. <i>Circulation</i> , 2006, 113, 1730-1737.	1.6	176
427	C-terminal Domain of Kv4.2 and Associated KChIP2 Interactions Regulate Functional Expression and Gating of Kv4.2. <i>Journal of Biological Chemistry</i> , 2006, 281, 27134-27144.	1.6	20
428	Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. <i>Genes and Development</i> , 2006, 20, 2355-2360.	2.7	151
429	The pathology of atrial fibrillation in dogs. <i>Journal of Veterinary Cardiology</i> , 2005, 7, 121-129.	0.3	37
430	Driver Regions in Atrial Fibrillation Associated with Congestive Heart Failure: Where Are They, and What Are They Telling Us?. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 050928083434001.	0.8	6
431	Mechanisms of Atrial Fibrillation: Lessons From Animal Models. <i>Progress in Cardiovascular Diseases</i> , 2005, 48, 9-28.	1.6	213
432	Atrial cell action potential parameter fitting using genetic algorithms. <i>Medical and Biological Engineering and Computing</i> , 2005, 43, 561-571.	1.6	75

#	ARTICLE	IF	CITATIONS
433	Atrial Fibrillation: Basic Mechanisms, Remodeling and Triggers. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2005, 13, 181-193.	0.6	96
434	Local delivery of 17 β -estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1042-1047.	1.8	21
435	Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 289, H1002-H1012.	1.5	103
436	Comparison of ion channel distribution and expression in cardiomyocytes of canine pulmonary veins versus left atrium. <i>Cardiovascular Research</i> , 2005, 65, 104-116.	1.8	88
437	Novel Targets for Cardiac Antiarrhythmic Drug Development. <i>Current Pharmaceutical Design</i> , 2005, 11, 1959-1974.	0.9	9
438	Functional expression of Kir2.x in human aortic endothelial cells: the dominant role of Kir2.2. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 289, C1134-C1144.	2.1	58
439	Atrial fibrillation-associated minK38C/S polymorphism modulates delayed rectifier current and membrane localization. <i>Cardiovascular Research</i> , 2005, 67, 520-528.	1.8	95
440	Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model. <i>Cardiovascular Research</i> , 2005, 66, 472-481.	1.8	151
441	Mechanisms of Atrial Fibrillation Termination by Pure Sodium Channel Blockade in an Ionically-Realistic Mathematical Model. <i>Circulation Research</i> , 2005, 96, e35-47.	2.0	126
442	Atrial Tachycardia Remodeling of Pulmonary Vein Cardiomyocytes. <i>Circulation</i> , 2005, 111, 728-735.	1.6	87
443	A Single Residue in the S6 Transmembrane Domain Governs the Differential Flecainide Sensitivity of Voltage-Gated Potassium Channels. <i>Molecular Pharmacology</i> , 2005, 68, 305-316.	1.0	18
444	Arrhythmogenic right ventricular dysplasia type 1 and mutations in transforming growth factor β 3 gene regulatory regions: a breakthrough?. <i>Cardiovascular Research</i> , 2005, 65, 302-304.	1.8	7
445	Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 332-333.	3.3	5
446	Wave block formation in homogeneous excitable media following premature excitations: Dependence on restitution relations. <i>Physical Review E</i> , 2005, 72, 031919.	0.8	21
447	Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation. <i>Circulation</i> , 2005, 112, 471-481.	1.6	215
448	Aldosterone antagonism and atrial fibrillation: time for clinical assessment?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2005, 26, 2079-2080.	1.0	11
449	Specific potassium channel blockade for arrhythmia prevention in the ionically remodeled failing heart: Peril or panacea?. <i>Heart Rhythm</i> , 2005, 2, 739-740.	0.3	1
450	Regional discrepancies in ionic currents and arrhythmia susceptibility: Clinical relevance. <i>Heart Rhythm</i> , 2005, 2, 177-178.	0.3	0

#	ARTICLE	IF	CITATIONS
451	Pulmonary vein cellular electrophysiology and atrial fibrillation: Does basic research help us understand clinical pulmonary-vein arrhythmogenesis?. <i>Heart Rhythm</i> , 2005, 2, 1346.	0.3	3
452	Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: A new unifying concept with basic and clinical relevance. <i>Heart Rhythm</i> , 2005, 2, 632-633.	0.3	11
453	Electrophysiological and atrial antiarrhythmic effects of a novel IK _{Kr} /Kv1.5 blocker in dogs. <i>Heart Rhythm</i> , 2005, 2, S180.	0.3	18
454	Ionic Determinants of Functional Reentry in a 2-D Model of Human Atrial Cells During Simulated Chronic Atrial Fibrillation. <i>Biophysical Journal</i> , 2005, 88, 3806-3821.	0.2	232
455	The beneficial effects of a novel specific chymase inhibitor, SUNC8257, on congestive heart failure-related atrial remodeling in dogs. <i>Heart Rhythm</i> , 2005, 2, S95-S96.	0.3	0
456	Are all sodium channel blockers created equal? Clinical-basic correlations based on observations in Brugada syndrome. <i>Heart Rhythm</i> , 2005, 2, 261-262.	0.3	4
457	Atrial Tachycardia, Flutter, and Fibrillation. , 2005, , 283-363.		8
458	Mechanisms of atrial remodeling and clinical relevance. <i>Current Opinion in Cardiology</i> , 2005, 20, 21-5.	0.8	81
459	Atrial fibrillation: basic and clinical research at the Montreal Heart Institute. <i>Canadian Journal of Cardiology</i> , 2005, 21, 1091-6.	0.8	0
460	Differential Alterations of Receptor Densities of Three Muscarinic Acetylcholine Receptor Subtypes and Current Densities of the Corresponding K ⁺ Channels in Canine Atria with Atrial Fibrillation Induced by Experimental Congestive Heart Failure. <i>Cellular Physiology and Biochemistry</i> , 2004, 14, 31-40.	1.1	45
461	Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs. <i>Circulation</i> , 2004, 110, 2313-2319.	1.6	249
462	Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?. <i>Cmaj</i> , 2004, 171, 752-753.	0.9	0
463	Dissociation Between Ionic Remodeling and Ability to Sustain Atrial Fibrillation During Recovery From Experimental Congestive Heart Failure. <i>Circulation</i> , 2004, 109, 412-418.	1.6	172
464	Defining "Culprit Mechanisms" in Arrhythmogenic Cardiac Remodeling. <i>Circulation Research</i> , 2004, 94, 1403-1405.	2.0	20
465	KvLQT1 Modulates the Distribution and Biophysical Properties of HERG. <i>Journal of Biological Chemistry</i> , 2004, 279, 1233-1241.	1.6	67
466	Impairment of HERG K ⁺ Channel Function by Tumor Necrosis Factor- α . <i>Journal of Biological Chemistry</i> , 2004, 279, 13289-13292.	1.6	125
467	Atrial Ionic Remodeling Induced by Atrial Tachycardia in the Presence of Congestive Heart Failure. <i>Circulation</i> , 2004, 110, 1520-1526.	1.6	106
468	In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. <i>Cardiovascular Research</i> , 2004, 61, 705-714.	1.8	30

#	ARTICLE	IF	CITATIONS
469	Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. <i>Cardiovascular Research</i> , 2004, 63, 236-244.	1.8	237
470	Potential mechanisms for the enhancement of HERG K ⁺ channel function by phospholipid metabolites. <i>British Journal of Pharmacology</i> , 2004, 141, 586-599.	2.7	26
471	Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects. <i>British Journal of Pharmacology</i> , 2004, 142, 1300-1308.	2.7	97
472	Single-channel recordings of a rapid delayed rectifier current in adult mouse ventricular myocytes: basic properties and effects of divalent cations. <i>Journal of Physiology</i> , 2004, 556, 401-413.	1.3	26
473	Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. <i>Journal of Physiology</i> , 2004, 557, 583-597.	1.3	142
474	Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. <i>Journal of Physiology</i> , 2004, 561, 735-748.	1.3	141
475	The Kv4.2 N-terminal restores fast inactivation and confers KChIP2 modulatory effects on N-terminal-deleted Kv1.4 channels. <i>Pflugers Archiv European Journal of Physiology</i> , 2004, 449, 235-47.	1.3	8
476	Is Atrial Remodeling a Viable Target for Prevention of Atrial Fibrillation Recurrence?. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 885-886.	0.8	2
477	Age, gender, and supraventricular arrhythmias: Roles of ion channels, connexins, and tissue architecture?. <i>Heart Rhythm</i> , 2004, 1, 397-398.	0.3	9
478	Ionic current abnormalities associated with prolonged action potentials in cardiomyocytes from diseased human right ventricles. <i>Heart Rhythm</i> , 2004, 1, 460-468.	0.3	112
479	The effect of vagally induced dispersion of action potential duration on atrial arrhythmogenesis. <i>Heart Rhythm</i> , 2004, 1, 334-344.	0.3	101
480	The clinical relevance of connexin gating: how to control communication in the heart. <i>Heart Rhythm</i> , 2004, 1, 234.	0.3	5
481	Post-transcriptional alterations in the expression of cardiac Na ⁺ channel subunits in chronic heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 91-100.	0.9	65
482	Cost Evaluation of Rhythm Control Methods for Atrial Fibrillation: Evidence from CTAF. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 211-214.	0.9	2
483	Properties, Expression and Potential Roles of Cardiac K ⁺ Channel Accessory Subunits: MinK, MiRPs, KChIP, and KChAP. <i>Journal of Membrane Biology</i> , 2003, 194, 141-152.	1.0	58
484	Basic Electrophysiology of the Pulmonary Veins and Their Role in Atrial Fibrillation: Precipitators, Perpetuators, and Perplexers. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 1372-1375.	0.8	57
485	Mechanisms of Termination of Atrial Fibrillation by Class I Antiarrhythmic Drugs: Journal of Cardiovascular Electrophysiology, 2003, 14, S133-S139.	0.8	32
486	Pharmacological Prevention of Atrial Tachycardia Induced Atrial Remodeling as a Potential Therapeutic Strategy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 752-764.	0.5	35

#	ARTICLE	IF	CITATIONS
487	Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. <i>British Journal of Pharmacology</i> , 2003, 138, 1475-1484.	2.7	24
488	Lost anchors cost lives. <i>Nature</i> , 2003, 421, 587-589.	13.7	9
489	Identification of atrial tissue in pulmonary veins using intravascular ultrasound. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 982-987.	1.2	25
490	Normal function of HERG K ⁺ channels expressed in HEK293 cells requires basal protein kinase B activity. <i>FEBS Letters</i> , 2003, 534, 125-132.	1.3	53
491	Tissue-specific expression of two human Cav 1.2 isoforms under the control of distinct 5' flanking regulatory elements. <i>FEBS Letters</i> , 2003, 546, 349-354.	1.3	47
492	Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium. <i>Circulation</i> , 2003, 107, 1440-1446.	1.6	157
493	Atrial Electrophysiology and Mechanisms of Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003, 8, S5-S11.	1.0	52
494	Intra-Atrial Pressure Increases Rate and Organization of Waves Emanating From the Superior Pulmonary Veins During Atrial Fibrillation. <i>Circulation</i> , 2003, 108, 668-671.	1.6	311
495	Molecular basis of species-specific expression of repolarizing K ⁺ currents in the heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H1641-H1649.	1.5	107
496	Barium block of Kir2 and human cardiac inward rectifier currents: evidence for subunit-heteromeric contribution to native currents. <i>Cardiovascular Research</i> , 2003, 59, 328-338.	1.8	102
497	Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. <i>Cardiovascular Research</i> , 2003, 60, 315-325.	1.8	230
498	Atrial Ischemia Promotes Atrial Fibrillation in Dogs. <i>Circulation</i> , 2003, 107, 1930-1936.	1.6	233
499	Canine Ventricular KCNE2 Expression Resides Predominantly in Purkinje Fibers. <i>Circulation Research</i> , 2003, 93, 189-191.	2.0	57
500	Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. <i>Journal of Physiology</i> , 2003, 551, 801-813.	1.3	224
501	Rhythm versus rate control for atrial fibrillation management: what recent randomized clinical trials allow us to affirm. <i>Cmaj</i> , 2003, 168, 572-3.	0.9	3
502	Prognostic significance of ventricular arrhythmias post-myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2003, 19, 1393-404.	0.8	21
503	Predicting the entrainment of reentrant cardiac waves using phase resetting curves. <i>Physical Review E</i> , 2002, 65, 021908.	0.8	39
504	Development of a computer algorithm for the detection of phase singularities and initial application to analyze simulations of atrial fibrillation. <i>Chaos</i> , 2002, 12, 764-778.	1.0	32

#	ARTICLE	IF	CITATIONS
505	Consequences of Atrial Tachycardia-Induced Remodeling Depend on the Preexisting Atrial Substrate. <i>Circulation</i> , 2002, 105, 251-257.	1.6	73
506	Cholinergic Atrial Fibrillation in a Computer Model of a Two-Dimensional Sheet of Canine Atrial Cells With Realistic Ionic Properties. <i>Circulation Research</i> , 2002, 90, E73-87.	2.0	237
507	Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. <i>European Heart Journal</i> , 2002, 23, 1050-1056.	1.0	30
508	Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. <i>Cardiovascular Research</i> , 2002, 54, 456-461.	1.8	214
509	Effects of inhibiting Na ⁺ /H ⁺ -exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. <i>Cardiovascular Research</i> , 2002, 54, 438-446.	1.8	74
510	Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H1031-H1041.	1.5	219
511	Cellular electrophysiology of atrial fibrillation. <i>Cardiovascular Research</i> , 2002, 54, 259-269.	1.8	86
512	Spotlight on atrial fibrillation—the 'complete arrhythmia'. <i>Cardiovascular Research</i> , 2002, 54, 197-203.	1.8	23
513	Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs. <i>Circulation</i> , 2002, 105, 2672-2678.	1.6	226
514	Comparison of Ion-Channel Subunit Expression in Canine Cardiac Purkinje Fibers and Ventricular Muscle. <i>Circulation Research</i> , 2002, 91, 790-797.	2.0	110
515	Properties of potassium currents in Purkinje cells of failing human hearts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H2495-H2503.	1.5	37
516	Effects of sustained β_2 -adrenergic stimulation on ionic currents of cultured adult guinea pig cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H880-H889.	1.5	44
517	Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?. <i>Cardiovascular Research</i> , 2002, 54, 347-360.	1.8	90
518	Remodeling of Ca ²⁺ -handling by atrial tachycardia: evidence for a role in loss of rate-adaptation. <i>Cardiovascular Research</i> , 2002, 54, 416-426.	1.8	38
519	Ultrarapid Delayed Rectifier K ⁺ Current in H9c2 Rat Ventricular Cell Line: Biophysical Property and Molecular Identity. <i>Cellular Physiology and Biochemistry</i> , 2002, 12, 215-226.	1.1	9
520	Differential Distribution of Cardiac Ion Channel Expression as a Basis for Regional Specialization in Electrical Function. <i>Circulation Research</i> , 2002, 90, 939-950.	2.0	366
521	New Approaches to Atrial Fibrillation Management. <i>Drugs</i> , 2002, 62, 2377-2397.	4.9	65
522	Differential distribution of Kir2.1 and Kir2.3 subunits in canine atrium and ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H1123-H1133.	1.5	90

#	ARTICLE	IF	CITATIONS
523	Time-dependent transients in an ionically based mathematical model of the canine atrial action potential. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H1437-H1451.	1.5	64
524	A Mathematical Model of Human Atrioventricular Nodal Function Incorporating Concealed Conduction. <i>Bulletin of Mathematical Biology</i> , 2002, 64, 1083-1099.	0.9	36
525	Dofetilide block involves interactions with open and inactivated states of HERG channels. <i>Pflügers Archiv European Journal of Physiology</i> , 2002, 443, 520-531.	1.3	58
526	Atrial Fibrillation and Congestive Heart Failure: Specific Considerations at the Intersection of Two Common and Important Cardiac Disease Sets. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 399-405.	0.8	182
527	A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. <i>Journal of Physiology</i> , 2002, 540, 15-27.	1.3	173
528	Kir2.4 and Kir2.1 K ⁺ channel subunits coassemble: a potential new contributor to inward rectifier current heterogeneity. <i>Journal of Physiology</i> , 2002, 544, 337-349.	1.3	46
529	New ideas about atrial fibrillation 50 years on. <i>Nature</i> , 2002, 415, 219-226.	13.7	1,364
530	New insights into the mechanisms and management of atrial fibrillation. <i>Cmaj</i> , 2002, 167, 1012-20.	0.9	13
531	HERG K ⁺ channel, a regulator of tumor cell apoptosis and proliferation. <i>Cancer Research</i> , 2002, 62, 4843-8.	0.4	172
532	Coronary artery endothelial protection after local delivery of 17 β -estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1570-1576.	1.2	50
533	Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H1075-H1080.	1.5	65
534	Expression of Multiple Subtypes of Muscarinic Receptors and Cellular Distribution in the Human Heart. <i>Molecular Pharmacology</i> , 2001, 59, 1029-1036.	1.0	106
535	Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. <i>Cardiovascular Research</i> , 2001, 52, 217-225.	1.8	101
536	Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. <i>Cardiovascular Research</i> , 2001, 49, 751-761.	1.8	119
537	Sodium Channel Inactivation Abnormalities Associated with Heart Disease: Ionic Remodeling and Arrhythmogenic Channelopathies. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 226-228.	0.8	1
538	Method for Simultaneous Epicardial and Endocardial Mapping of In Vivo Canine Heart: Application to Atrial Conduction Properties and Arrhythmia Mechanisms. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 548-555.	0.8	74
539	Title is missing!. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2001, 5, 263-267.	0.9	0
540	Title is missing!. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2001, 5, 162-165.	0.9	1

#	ARTICLE	IF	CITATIONS
541	Arrhythmogenic Ionic Remodeling Adaptive Responses with Maladaptive Consequences. Trends in Cardiovascular Medicine, 2001, 11, 295-301.	2.3	31
542	Oxidative Preconditioning and Apoptosis in L-cells. Journal of Biological Chemistry, 2001, 276, 26357-26364.	1.6	77
543	Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing-Induced Congestive Heart Failure. Circulation, 2001, 104, 2608-2614.	1.6	646
544	Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovascular Research, 2001, 49, 762-770.	1.8	93
545	Phospholipid Metabolite 1-Palmitoyl-Lysophosphatidylcholine Enhances Human Ether-a-Go-Go -Related Gene (HERG) K ⁺ Channel Function. Circulation, 2001, 104, 2645-2648.	1.6	33
546	Potential Ionic Mechanism for Repolarization Differences Between Canine Right and Left Atrium. Circulation Research, 2001, 88, 1168-1175.	2.0	173
547	Ionic Remodeling of Cardiac Purkinje Cells by Congestive Heart Failure. Circulation, 2001, 104, 2095-2100.	1.6	95
548	The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. Cardiovascular Research, 2001, 50, 75-84.	1.8	22
549	Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. Cardiovascular Research, 2001, 50, 85-96.	1.8	32
550	Effects of Ionic Remodeling on Cardiac Antiarrhythmic Drug Actions. Journal of Cardiovascular Pharmacology, 2001, 38, 809-811.	0.8	11
551	Molecular evidence for a role of Shaw (Kv3) potassium channel subunits in potassium currents of dog atrium. Journal of Physiology, 2000, 527, 467-478.	1.3	31
552	State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes. Journal of Physiology, 2000, 526, 265-278.	1.3	20
553	Mechanisms of Antiarrhythmic Drug Actions. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 186-189.	0.9	0
554	Amiodarone Oral. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 262-269.	0.9	1
555	A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H466-H474.	1.5	38
556	Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1767-H1785.	1.5	138
557	Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine, 2000, 342, 913-920.	13.9	1,071
558	Randomized Trial Comparing Intravenous Nitroglycerin and Heparin for Treatment of Unstable Angina Secondary to Restenosis After Coronary Artery Angioplasty. Circulation, 2000, 101, 955-961.	1.6	18

#	ARTICLE	IF	CITATIONS
559	Ionic Remodeling in the Heart. <i>Circulation Research</i> , 2000, 87, 440-447.	2.0	151
560	Dose-Dependence of 4-Aminopyridine Plasma Concentrations and Electrophysiological Effects in Dogs. <i>Circulation</i> , 2000, 101, 1179-1184.	1.6	37
561	Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation. <i>Circulation</i> , 2000, 102, 104-112.	1.6	103
562	Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. <i>Cardiovascular Research</i> , 2000, 46, 151-161.	1.8	26
563	Acquired delayed rectifier channelopathies: how heart disease and antiarrhythmic drugs mimic potentially-lethal congenital cardiac disorders. <i>Cardiovascular Research</i> , 2000, 48, 188-190.	1.8	17
564	Nicotine Is a Potent Blocker of the Cardiac A-Type K ⁺ Channels. <i>Circulation</i> , 2000, 102, 1165-1171.	1.6	102
565	Effects of Experimental Heart Failure on Atrial Cellular and Ionic Electrophysiology. <i>Circulation</i> , 2000, 101, 2631-2638.	1.6	356
566	Basic Mechanisms of Atrial Fibrillation—Very New Insights into Very Old Ideas. <i>Annual Review of Physiology</i> , 2000, 62, 51-77.	5.6	164
567	Azimilide. <i>Drugs</i> , 2000, 59, 279-278.	4.9	1
568	Oita International Electrocardiology Symposium 2000 —Electrophysiology and Management of Lethal Arrhythmias in the New Millennium: From Genes to Bedside— Japanese Journal of Electrocardiology, 2000, 20, 6-10.	0.0	0
569	Electrophysiological mechanisms by which hypothyroidism delays repolarization in guinea pig hearts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 277, H211-H220.	1.5	21
570	Transmembrane Ca contributes to rate-dependent changes of action potentials in human ventricular myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H98-H106.	1.5	73
571	Dihydropyridine and beta adrenergic receptor binding in dogs with tachycardia-induced atrial fibrillation. <i>Cardiovascular Research</i> , 1999, 42, 434-442.	1.8	47
572	Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation. <i>Cardiovascular Research</i> , 1999, 42, 298-308.	1.8	138
573	Molecular Mechanisms Underlying Ionic Remodeling in a Dog Model of Atrial Fibrillation. <i>Circulation Research</i> , 1999, 84, 776-784.	2.0	328
574	Ionic Determinants of Atrial Fibrillation and Ca ²⁺ -Channel Abnormalities. <i>Circulation Research</i> , 1999, 85, 473-476.	2.0	50
575	Effects of Probucol on Vascular Remodeling After Coronary Angioplasty. <i>Circulation</i> , 1999, 99, 30-35.	1.6	134
576	Potential Molecular Basis of Different Physiological Properties of the Transient Outward K ⁺ Current in Rabbit and Human Atrial Myocytes. <i>Circulation Research</i> , 1999, 84, 551-561.	2.0	193

#	ARTICLE	IF	CITATIONS
577	Promotion of Atrial Fibrillation by Heart Failure in Dogs. <i>Circulation</i> , 1999, 100, 87-95.	1.6	1,273
578	Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. <i>Cardiovascular Research</i> , 1999, 42, 477-489.	1.8	256
579	The T-Type Ca ²⁺ Channel Blocker Mibefradil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs. <i>Circulation</i> , 1999, 100, 2191-2197.	1.6	148
580	Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. <i>Journal of Physiology</i> , 1999, 516, 385-398.	1.3	33
581	Electrophysiologic Remodeling... <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 1553-1556.	0.8	39
582	The Molecular and Ionic Specificity of Antiarrhythmic Drug Actions. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 272-282.	0.8	90
583	Optimal Management with Class I and Class III Antiarrhythmic Drugs Should Be Done in the Outpatient Setting.. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 472-481.	0.8	23
584	The Pathophysiology of Atrial Fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1999, 3, 85-87.	0.9	0
585	Atrial Fibrillation: Experimental and Theoretical Developments. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1999, 3, 110-112.	0.9	0
586	Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. <i>American Journal of Cardiology</i> , 1999, 84, 11-19.	0.7	222
587	The mechanisms of enhanced vulnerability to atrial fibrillation caused by atrial tachycardia-induced electrical remodeling: Insights from combined activation and refractoriness mapping. <i>Journal of Electrocardiology</i> , 1999, 32, 139.	0.4	0
588	Cardiac Ultrarapid Delayed Rectifiers. <i>Cellular Physiology and Biochemistry</i> , 1999, 9, 217-226.	1.1	125
589	A spotlight on electrophysiological remodeling and the molecular biology of ion channels. <i>Cardiovascular Research</i> , 1999, 42, 267-269.	1.8	5
590	Is There a Future for Antiarrhythmic Drug Therapy?. <i>Drugs</i> , 1998, 56, 767-781.	4.9	22
591	Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. <i>Cardiovascular Research</i> , 1998, 37, 567-577.	1.8	65
592	Cellular Mechanisms of Atrial Contractile Dysfunction Caused by Sustained Atrial Tachycardia. <i>Circulation</i> , 1998, 98, 719-727.	1.6	197
593	Ionic Mechanisms of Regional Action Potential Heterogeneity in the Canine Right Atrium. <i>Circulation Research</i> , 1998, 83, 541-551.	2.0	186
594	Effects of the Diuretic Agent Indapamide on Na ⁺ , Transient Outward, and Delayed Rectifier Currents in Canine Atrial Myocytes. <i>Circulation Research</i> , 1998, 83, 158-166.	2.0	25

#	ARTICLE	IF	CITATIONS
595	Importance of Refractoriness Heterogeneity in the Enhanced Vulnerability to Atrial Fibrillation Induction Caused by Tachycardia-Induced Atrial Electrical Remodeling. <i>Circulation</i> , 1998, 98, 2202-2209.	1.6	324
596	Differential Distribution of Inward Rectifier Potassium Channel Transcripts in Human Atrium Versus Ventricle. <i>Circulation</i> , 1998, 98, 2422-2428.	1.6	199
597	Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K ⁺ current, on repolarization in human and guinea pig ventricular myocytes. <i>Cardiovascular Research</i> , 1998, 38, 441-450.	1.8	206
598	Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. <i>Cardiovascular Research</i> , 1998, 37, 627-635.	1.8	77
599	Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H301-H321.	1.5	830
600	Characterization of a transient outward K ⁺ current with inward rectification in canine ventricular myocytes. <i>American Journal of Physiology - Cell Physiology</i> , 1998, 274, C577-C585.	2.1	251
601	Ultraslow delayed rectifier current inactivation in human atrial myocytes: properties and consequences. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H1717-H1725.	1.5	54
602	Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalization in human cardiac myocytes. <i>Cardiovascular Research</i> , 1998, 38, 395-404.	1.8	34
603	Probulol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty. <i>New England Journal of Medicine</i> , 1997, 337, 365-372.	13.9	578
604	Insights into Mechanisms of Antiarrhythmic Drug Action From Experimental Models of Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 469-480.	0.8	51
605	Pilot Study and Protocol of the Canadian Trial of Atrial Fibrillation (CTAF). <i>American Journal of Cardiology</i> , 1997, 80, 464-468.	0.7	34
606	Atrial Fibrillation: Experimental and Theoretical Developments. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997, 1, 49-51.	0.9	0
607	The Pathophysiology of Atrial Fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997, 1, 25-26.	0.9	1
608	Functional Mechanisms Underlying Tachycardia-Induced Sustained Atrial Fibrillation in a Chronic Dog Model. <i>Circulation</i> , 1997, 96, 4027-4035.	1.6	326
609	Evidence That Outwardly Rectifying Cl ⁻ Channels Underlie Volume-Regulated Cl ⁻ Currents in Heart. <i>Circulation Research</i> , 1997, 80, 103-113.	2.0	65
610	Antisense Oligodeoxynucleotides Directed Against Kv1.5 mRNA Specifically Inhibit Ultraslow Delayed Rectifier K ⁺ Current in Cultured Adult Human Atrial Myocytes. <i>Circulation Research</i> , 1997, 80, 572-579.	2.0	257
611	Ionic Remodeling Underlying Action Potential Changes in a Canine Model of Atrial Fibrillation. <i>Circulation Research</i> , 1997, 81, 512-525.	2.0	659
612	Tachycardia-Induced Changes in Na ⁺ Current in a Chronic Dog Model of Atrial Fibrillation. <i>Circulation Research</i> , 1997, 81, 1045-1052.	2.0	209

#	ARTICLE	IF	CITATIONS
613	Demonstration of an Inward Na ⁺ -Ca ²⁺ Exchange Current in Adult Human Atrial Myocytes. <i>Annals of the New York Academy of Sciences</i> , 1996, 779, 525-528.	1.8	18
614	Relative Role of Alkalosis and Sodium Ions in Reversal of Class I Antiarrhythmic Drug-Induced Sodium Channel Blockade by Sodium Bicarbonate. <i>Circulation</i> , 1996, 94, 1954-1961.	1.6	54
615	Protein Kinase C Activates ATP-Sensitive K ⁺ Current in Human and Rabbit Ventricular Myocytes. <i>Circulation Research</i> , 1996, 78, 492-498.	2.0	134
616	Evidence for Two Components of Delayed Rectifier K ⁺ Current in Human Ventricular Myocytes. <i>Circulation Research</i> , 1996, 78, 689-696.	2.0	409
617	Adrenergic Modulation of Ultrarapid Delayed Rectifier K ⁺ Current in Human Atrial Myocytes. <i>Circulation Research</i> , 1996, 78, 903-915.	2.0	113
618	Is Cardiac Migraine a Clinical Entity?. <i>Clinical Nuclear Medicine</i> , 1995, 20, 403-406.	0.7	0
619	Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study*. <i>Journal of Nuclear Cardiology</i> , 1995, 2, 3-17.	1.4	164
620	Long-term risk stratification with dipyridamole imaging. <i>American Heart Journal</i> , 1995, 129, 880-886.	1.2	37
621	Newer developments in the management of atrial fibrillation. <i>American Heart Journal</i> , 1995, 130, 1094-1106.	1.2	87
622	Idiopathic atrial fibrillation in dogs: Electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide. <i>Journal of the American College of Cardiology</i> , 1995, 26, 277-286.	1.2	53
623	Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs. <i>Circulation</i> , 1995, 92, 1300-1311.	1.6	37
624	Mechanisms of Ischemic Preconditioning in Rat Hearts. <i>Circulation</i> , 1995, 92, 2259-2265.	1.6	107
625	β-Adrenergic Control of Volume-Regulated Cl ⁻ Currents in Rabbit Atrial Myocytes. <i>Circulation Research</i> , 1995, 77, 379-393.	2.0	79
626	Rapid and slow components of delayed rectifier current in human atrial myocytes. <i>Cardiovascular Research</i> , 1994, 28, 1540-1546.	1.8	218
627	Absence of pharmacokinetic interaction between amiodarone and lidocaine. <i>American Journal of Cardiology</i> , 1994, 73, 92-94.	0.7	5
628	Dynamic Behavior of the Atrioventricular Node. <i>Journal of Cardiovascular Electrophysiology</i> , 1994, 5, 90-102.	0.8	33
629	The Treatment of Atrial Fibrillation. <i>Drugs</i> , 1994, 48, 345-371.	4.9	83
630	Comparative mechanisms of action of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1993, 72, F13-F17.	0.7	36

#	ARTICLE	IF	CITATIONS
631	Antiarrhythmic Prophylaxis after Acute Myocardial Infarction. <i>Drugs</i> , 1993, 45, 9-14.	4.9	8
632	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. <i>Journal of Cardiovascular Electrophysiology</i> , 1992, 3, 266-280.	0.8	38
633	Effects of flecainide on the rate dependence of atrial refractoriness, atrial repolarization and atrioventricular node conduction in anesthetized dogs. <i>Journal of the American College of Cardiology</i> , 1992, 19, 1335-1342.	1.2	26
634	Multivariate clinical models and quantitative dipyridamole-thallium imaging to predict cardiac morbidity and death after vascular reconstruction. <i>Journal of Vascular Surgery</i> , 1991, 14, 160-169.	0.6	77
635	Antiarrhythmic Drug Classifications. <i>Drugs</i> , 1991, 41, 672-701.	4.9	77
636	Prevention of action potential duration accommodation to heart rate "A new antiarrhythmic mechanism?. <i>Journal of the American College of Cardiology</i> , 1991, 17, A360.	1.2	1
637	Pharmacologic Response of Cesium-Induced Ventricular Tachyarrhythmias in Anesthetized Dogs. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 15, 552-561.	0.8	17
638	Cycle Length Alternation During Supraventricular Tachycardia: Occurrence and Mechanism in a Canine Model of AV Reentrant Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990, 13, 314-325.	0.5	8
639	Electrophysiological Effects of alpha-Adrenergic Stimulation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990, 13, 578-582.	0.5	16
640	Determinants and significance of diltiazem plasma concentrations after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1990, 66, 1422-1428.	0.7	5
641	What is an antiarrhythmic drug? From clinical trials to fundamental concepts. <i>American Journal of Cardiology</i> , 1990, 66, 96-99.	0.7	18
642	Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. <i>American Journal of Medicine</i> , 1990, 89, 235-238.	0.6	111
643	Attenuation of Class 3 and Sinus Node Effects of Amiodarone by Experimental Hypothyroidism. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 13, 447-450.	0.8	16
644	Sinus Node Dysfunction and Sudden Cardiac Death Following Treatment with Encainide. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1989, 12, 1607-1612.	0.5	4
645	Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. <i>Journal of the American College of Cardiology</i> , 1989, 13, 1190-1194.	1.2	45
646	Recent Advances in Understanding the Pharmacology of Amiodarone. <i>Drugs</i> , 1988, 36, 121-131.	4.9	43
647	Bevantolol Disposition in Patients with Hepatic Cirrhosis. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 962-966.	1.0	2
648	Effect of frequent ventricular ectopy on myocardial infarct size in dogs. <i>Cardiovascular Research</i> , 1987, 21, 286-292.	1.8	3

#	ARTICLE	IF	CITATIONS
649	Effects of taurine depletion on rat cardiac electrophysiology: and studies. Life Sciences, 1987, 40, 1017-1026.	2.0	33
650	The Pharmacokinetics of Lignocaine and β^2 -Adrenoceptor Antagonists in Patients with Acute Myocardial Infarction. Clinical Pharmacokinetics, 1987, 13, 293-316.	1.6	40
651	Relationship Between an Arrhythmogenic Action of Lidocaine and Its Effects on Excitation Patterns in Acutely Ischemic Porcine Myocardium. Journal of Cardiovascular Pharmacology, 1986, 8, 126-136.	0.8	40
652	Effects of encainide on the inducibility of ventricular arrhythmia in normal anesthetized dogs. Journal of Tongji Medical University, 1986, 6, 60-66.	0.1	0
653	Age-dependent lidocaine disposition in patients with acute myocardial infarction. Clinical Pharmacology and Therapeutics, 1985, 37, 381-386.	2.3	31
654	Lidocaine " problems in understanding an antiarrhythmic drug. Trends in Pharmacological Sciences, 1982, 3, 297-300.	4.0	1
655	Use of Excessive Lidocaine Concentrations for Local Anesthesia. New England Journal of Medicine, 1980, 302, 122-122.	13.9	5
656	Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. American Journal of Cardiology, 1980, 45, 627-632.	0.7	73
657	Therapeutic Blood Lidocaine Concentrations after Local Anesthesia for Cardiac Electrophysiologic Studies. New England Journal of Medicine, 1979, 301, 418-420.	13.9	45